GenesisEngine designs complete biosynthetic pathways from target molecule to production-ready organism blueprint. AI-powered metabolic engineering that replaces petrochemistry with programmable biology.
400M tons of chemicals. $6T industry. 8% of global CO2. Biology can do better.
The $6 trillion global chemical industry produces 400 million tons of chemicals annually from petroleum. This process generates 5-8% of global CO2 emissions, consumes 10% of all fossil fuels, and creates toxic waste at massive scale.
Biology already manufactures chemicals at room temperature with zero toxic waste. A single yeast cell runs thousands of reactions with atomic precision no chemical plant can match. But reprogramming cells to produce specific target molecules takes 5-10 years and $50-200M per product. The design-build-test-learn cycle is too slow.
The bottleneck is design. There are 1030 possible pathway configurations for any target molecule. Current approaches test hundreds of variants over years. AI changes this equation entirely.
GenesisEngine is the AI platform that designs complete biomanufacturing pathways. Input a target molecule. Get a production-ready organism blueprint with enzyme candidates, thermodynamic analysis, host optimization, and genetic construct design.
Given a target molecule, our AI searches 22,000+ enzymatic reactions (KEGG, MetaCyc) and designs novel enzymes (RFdiffusion2) to assemble a complete biosynthetic pathway. Each pathway is scored on thermodynamic feasibility, cofactor balance, and predicted yield.
The designed pathway is computationally inserted into the optimal host organism (E. coli, yeast, C. necator for CO2 fixation). Genome-scale metabolic models predict flux distribution and optimize the genetic background for maximum production.
The optimized strain is simulated at industrial scale, predicting titer, rate, and yield in production bioreactors. Know what will work at 10,000L before touching a pipette.
Triple the 2022 level. Investors are pouring capital into the bioeconomy.
Federal commitment to domestic biomanufacturing capacity build-out.
Corporate ESG commitments driving demand for bio-based chemical alternatives.
RFdiffusion2 (Dec 2025) generates production-grade enzymes from text prompts.
Three convergent breakthroughs in the last 18 months make GenesisEngine possible for the first time in history. The enzyme design tools, biofoundry automation, and biological foundation models are all reaching maturity simultaneously.
Dec 2025 -- Institute for Protein Design
Generates novel enzymes with catalytic proficiency comparable to natural enzymes. Prior methods produced only trace-level activity. This is a 100x improvement in AI enzyme design.
BioAutomata -- 2025
Fully automated design-build-test-learn cycles. Optimizes metabolic pathways while testing less than 1% of the variant space. Removes human from the loop after initial query.
Multi-omics foundation models
Computational models simulating entire cellular systems. Predict metabolic flux from pathway design. Enable system-level reasoning about how engineered pathways interact with host metabolism.
Founder and CEO
15+ years in AI/ML. Former Head of AI Innovation at Motorola Solutions. Computational biology research at Bar-Ilan University (BINA). Founder of Ultra Deep Tech (AI safety lab). Background spanning deep reinforcement learning, cybersecurity AI, and biomathematics. M.Sc. Industrial Engineering, B.Sc. Mathematics and Physics.
LinkedIn ProfileTraditional biotech startups spend $10-50M before writing a line of code -- on lab space, equipment, and wet lab personnel. GenesisEngine is computation-first. AI designs the pathways. Biofoundry partners validate them. This capital-efficient model means we can iterate 100x faster than lab-based competitors and reach product-market fit with software economics.
Metabolic engineering, synthetic biology, biomanufacturing scale-up, bioprocess engineering
ML engineers, metabolic engineers, synbio researchers. Get in touch
Pathway designer live. First 500 researchers on the platform.
Raise $1.5M. Hire founding ML and synbio engineers.
RFdiffusion2 integration. Enterprise API. First biofoundry validations.
Raise $5M. 10+ validated pathways. First commercial pathway design.
First AI-designed organism in commercial bioproduction.
GenesisEngine is in development. Join the waitlist to get early access when we launch. Researchers and biofoundry operators get priority.